Literature DB >> 1701178

Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes.

G I Johnston1, G A Bliss, P J Newman, R P McEver.   

Abstract

GMP-140, an inducible granule membrane protein of platelets and endothelial cells, is a member of the selectin family of cell surface receptors that mediate interactions of leukocytes with the blood vessel wall. These molecules all contain an N-terminal lectin-like domain, followed by an epidermal growth factor-like domain, a variable number of consensus repeats related to those in complement-binding proteins, a transmembrane domain, and a cytoplasmic tail. Two variant cDNAs for GMP-140 have been identified, one predicting a soluble form of the molecule lacking the transmembrane domain and the other predicting a molecule containing eight instead of nine consensus repeats. Here we describe the organization of the human gene encoding GMP-140, which spans over 50 kilobase pairs and contains 17 exons. Almost all exons encode distinct structural domains, including the lectin-like domain, the epidermal growth factor-like domain, each of the nine consensus repeats, and the transmembrane region. Each of the two deletions found in the variant cDNAs is precisely encoded by an exon, suggesting that these forms of GMP-140 are derived from alternative splicing of mRNA. By using the polymerase chain reaction, transcripts encoding the putative soluble form of GMP-140 can be amplified from both platelet and endothelial cell RNA. The structure of the GMP-140 gene supports the concept that the selectins evolved as a result of exon duplication and rearrangement.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701178

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  P-Selectin: Basic Aspects.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

Review 2.  Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies.

Authors:  F Andreotti; I Porto; F Crea; A Maseri
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

3.  Pro-coagulant state resulting from high levels of soluble P-selectin in blood.

Authors:  P André; D Hartwell; I Hrachovinová; S Saffaripour; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  Serum-soluble selectin levels in patients with Behçet's disease.

Authors:  Aşkin Ateş; Olcay Aydintuğ Tiryaki; Umit Olmez; Hüseyin Tutkak
Journal:  Clin Rheumatol       Date:  2007-01-06       Impact factor: 2.980

Review 5.  Selectins.

Authors:  M P Bevilacqua; R M Nelson
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

6.  An atypical sorting determinant in the cytoplasmic domain of P-selectin mediates endosomal sorting.

Authors:  K S Straley; B L Daugherty; S E Aeder; A L Hockenson; K Kim; S A Green
Journal:  Mol Biol Cell       Date:  1998-07       Impact factor: 4.138

Review 7.  Mechanisms of dendritic cell trafficking across the blood-brain barrier.

Authors:  Divya Sagar; Catherine Foss; Rasha El Baz; Martin G Pomper; Zafar K Khan; Pooja Jain
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-06       Impact factor: 4.147

8.  Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease.

Authors:  M Göke; J C Hoffmann; J Evers; H Krüger; M P Manns
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

9.  Circulating soluble P-selectin must dimerize to promote inflammation and coagulation in mice.

Authors:  Sumith R Panicker; Padmaja Mehta-D'souza; Nan Zhang; Arkadiusz G Klopocki; Bojing Shao; Rodger P McEver
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

10.  Formation of sulphidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit.

Authors:  A Sala; G Rossoni; C Buccellati; F Berti; G Folco; J Maclouf
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.